翰宇藥業(300199.SZ):財務總監魏紅辭職 由塗鴻鴻接任
格隆匯7月12日丨翰宇藥業(300199.SZ)宣佈,公司於近日收到公司財務總監魏紅提交的辭職報吿,魏紅因個人原因申請辭去財務總監職務,魏紅辭職後將不再擔任公司任何職務。根據《公司法》及《公司章程》有關規定,魏紅辭職報吿自送達公司董事會後生效。魏紅目前持有公司股份30.50萬股,佔公司總股本的0.03%,其配偶或其他關聯人未持有公司股份。
2021年7月9日召開的公司第四屆董事會第三十一次會議審議通過了《關於聘任公司財務總監的議案》,董事會同意聘任塗鴻鴻為公司財務總監,任期自董事會審議通過之日起至第四屆董事會屆滿之日。公司獨立董事就該次聘任公司財務總監發表了獨立意見,同意聘任塗鴻鴻為公司財務總監。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.